Shattuck Labs, Discloses Updated Interim Data From Phase 1B Dose Expansion Clinical Trial Of SL-172154 In Combination With Azacitidine In Frontline Higher-Risk Myelodysplastic Syndromes And TP53 Mutant Acute Myeloid Leukemia Patients
Portfolio Pulse from Benzinga Newsdesk
Shattuck Labs disclosed updated interim data from its Phase 1B clinical trial of SL-172154 in combination with Azacitidine for higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) patients. The trial showed a 67% Objective Response Rate (ORR) in HR-MDS patients and a 43% ORR in TP53m AML patients.
June 14, 2024 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shattuck Labs reported promising interim data from its Phase 1B clinical trial of SL-172154, showing a 67% ORR in HR-MDS patients and a 43% ORR in TP53m AML patients. This positive data could boost investor confidence and potentially drive the stock price up in the short term.
The positive interim data from the clinical trial indicates strong efficacy of SL-172154 in treating HR-MDS and TP53m AML patients. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100